Companies › CStone Pharmaceuticals
4 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cs-1003 (CS1003) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Hepatocellular Carcinoma | – |
| Lorlatinib ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor | ALK, EML4 | Phase 2 | Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer | May 2027 |
| CS2009 | – | Phase 1 | Advanced Solid Tumors | Jan 2027 |
| CS5007 | – | Phase 1 | Advanced Solid Tumors | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04194775 | Cs-1003 (CS1003) | Phase 3 | Hepatocellular Carcinoma | Oncology | Jun 2025 |
| NCT06741644 | CS2009 | Phase 1 | Advanced Solid Tumors | Oncology | Jan 2027 |
| NCT05297890 | Lorlatinib | Phase 2 | Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer | Oncology | May 2027 |
| NCT07622524 | CS5007 | Phase 1 | Advanced Solid Tumors | Oncology | Jan 2028 |
Shenzhen TargetRx TaiRx Nuvalent CSPC Megalith Biopharmaceutical Stemline Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.